Ibrutinib, a BTK inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity in allergic cancer patients receiving drug
Regan, Jennifer A., Petrich, Adam M., Dispenza, Melanie C., Ma, Shuo, Gordon, Leo I., Bochner, Bruce S.Volume:
139
Language:
english
Journal:
Journal of Allergy and Clinical Immunology
DOI:
10.1016/j.jaci.2016.12.748
Date:
February, 2017
File:
PDF, 126 KB
english, 2017